A 40 year old man with hereditary multiple exostoses (HME), affecting predominantly his left proximal tibia, distal femur, and proximal femur, underwent resection of an osteochondroma near the trochanter major of his left proximal femur because of malignant transformation of the cartilaginous cap towards secondary peripheral chondrosarcoma. The patient had a history of a papillary thyroid carcinoma four years previously. At examination of the resected specimen, a third malignant tumour, an intermediate grade osteosarcoma (grade II/IV), was found in the osseous stalk of the osteochondroma. Although no mutations were found in the EXT1 and EXT2 genes, the genes involved in HME, or in exons 5-8 of the p53 gene, the development of three malignancies before the age of 40 suggests that this patient is genetically prone to malignant transformation.
H
ereditary multiple exostoses (HME) is an autosomal dominant skeletal disorder characterised by the development of multiple osteochondromas (osteocartilaginous exostoses), resulting in a variety of orthopaedic deformities. HME is genetically heterogeneous, and two genes, EXT1 located at 8q24 and EXT2 located at 11p11-p12, have been characterised. [1] [2] [3] Osteochondroma has been shown to be a neoplastic disorder, documented by loss of heterozygosity at the EXT1 locus, DNA aneuploidy, and clonal karyotypic abnormalities. 4 The most serious complication is malignant transformation. The risk of developing a malignant tumour is estimated to be less than 5% in HME. Malignant transformation leads to a chondrosarcoma in 94% of these cases, and this has been shown to occur by subsequent additional genetic alterations. Osteosarcomas, fibrosarcomas, and malignant fibrous histiocytomas are encountered infrequently.
We present an unusual case of a patient with HME, who had a resection of an osteochondroma near the trochanter major of his left proximal femur demonstrating a secondary chondrosarcoma in the cartilaginous cap, in addition to an intermediate grade osteosarcoma in the stalk of the same osteochondroma.
CLINICAL HISTORY
In February 1995, a 40 year old man presented with recurrent pain in the greater trochanter of his left femur. The patient had a history of a papillary thyroid carcinoma four years previously ( fig 1A) and was known to have HME. Family history revealed multiple bony lesions in one of his two children, his father, and a nephew. Skeletal scintigraphy had demonstrated multiple active lesions.
At presentation a large (14 × 9 cm), firm, and slightly tender mass was palpated near the left trochanter major. The tissue mass seemed to be attached to the bone. The patient had been seen three years before for similar symptoms. Radiography, bone scintigraphy, and magnetic resonance (MR) imaging at that time revealed no indications for malignant transformation of the cartilaginous cap (fig 2A) . Although repeated radiography in 1995 did not show a significant change in the lesion, increased activity was seen at bone scintigraphy when compared with the previous scan ( fig 2B) . MR imaging ( fig 2C) showed that the lesion had grown to a size of 7 × 9 × 11 cm. After intravenous contrast administration a septal and nodular enhancement pattern was seen, suggesting progression towards secondary peripheral chondrosarcoma. A Jamshidi trocar biopsy revealed irregularly distributed chondrocytes and binucleated cells, confirming malignant transformation.
Subsequently, the patient was admitted for surgery. At operation, the exophytic tumour was excised en bloc with the biopsy scar and a layer of soft tissue. At the femoral site the stalk of the tumour was taken out with a part of the lateral femur and greater trochanter. Histopathological examination of the resected specimen showed the classic appearance of an osteochondroma, with a cartilaginous cap measuring about 7 cm in thickness, microscopically consistent with a grade I chondrosarcoma ( fig 1B) . Both macroscopically and microscopically a distinct, mainly circumscribed lesion measuring 2 cm was observed within the osseous stalk of the osteochondroma, which microscopically appeared to be an intermediate grade osteosarcoma (grade II/IV) ( fig 1C) . All resection margins were free of tumour. More than four years later the patient is well and free of disease.
MATERIALS AND METHODS

DNA isolation
DNA isolation from fresh frozen tissue of the secondary chondrosarcoma component was performed as described previously. 5 Normal DNA was isolated from peripheral blood lymphocytes of the same patient using a salting out procedure. 6 DNA isolation from the formalin fixed, grade II osteosarcoma component failed to yield appropriate DNA owing to decalcification procedures.
EXT1 and EXT2 mutation analysis
Polymerase chain reaction (PCR) and single strand conformational polymorphism (SSCP) analyses of all EXT1 and EXT2 exons were performed on chondrosarcoma tumour DNA as detailed previously, 4 and gel patterns were compared with other chondrosarcoma tumour samples. Abbreviations: HME, hereditary multiple exostoses; MR, magnetic resonance; PCR, polymerase chain reaction; SSCP, single strand conformational polymorphism p53 analysis Immunohistochemical reactions using monoclonal antibodies directed against p53 (clone DO-7; Dako, Glostrup, Denmark) were performed on formalin fixed, paraffin wax embedded tissue from the papillary thyroid carcinoma, the grade II osteosarcoma, and the grade I chondrosarcoma according to standard laboratory methods. 7 Mutation analysis was performed using PCR and direct sequencing of exons 5 to 8 on both normal and chondrosarcoma tumour DNA as described previously. 8 
RESULTS
EXT1 and EXT2 mutation analysis
Although our patient had a positive family history for multiple exostoses, no aberrant bands were detected in the EXT1 and EXT2 genes by SSCP.
p53 analysis
Both the papillary thyroid carcinoma and the chondrosarcoma failed to show p53 immunoreactivity, whereas the grade II osteosarcoma showed p53 overexpression (fig 3) . Both in normal DNA and in chondrosarcoma tumour DNA, no mutations were found in exons 5 to 8 of p53 by direct sequencing. Unfortunately, no appropriate DNA was available from the grade II osteosarcoma showing p53 overexpression, so a possible somatic mutation could not be demonstrated.
DISCUSSION
The patient described came from a family known to be affected by HME. HME is an autosomal dominant, genetically heterogeneous disorder, with an incomplete penetrance mostly in females. Two genes, EXT1 and EXT2, have been cloned to date. [1] [2] [3] Recently, the EXT1 and EXT2 genes were shown to be tumour suppressor genes. 4 The gene products are glycosyltransferases involved in the biosynthesis of cell surface heparan sulphate, 9 affecting diffusion of the morphogen Hedgehog. 10 Linkage to chromosome 19p has also been found, suggesting the existence of an EXT3 gene. 11 Malignant transformation of osteochondroma is estimated to occur in 1-5% of cases of HME. The suspicion of secondary chondrosarcoma is indicated by growth of the tumour after puberty, the presence of pain, or a thickness over 1 cm of the cartilaginous cap in adults. At present, the size of the cartilaginous cap can be well established with T2 weighted MR imaging. In our case, there was no doubt about the extensive presence of hyaline cartilage nodules as displayed by high signal intensity on the T2 weighted MR images in a lobular fashion, separated by low signal intensity septations.
The process of malignant transformation of osteochondroma is genetically represented by chromosomal instability, as was previously demonstrated by a high percentage of loss of heterozygosity involving various loci and a broad range of DNA ploidy. 7 The chondrosarcoma of our patient demonstrated near haploidy (DNA index, 0.56) and loss of heterozygosity for most chromosomes tested. 12 At the protein level, malignant transformation is characterised by upregulation of the expression of parathyroid hormone releasing protein and Bcl-2, two putative downstream effectors of EXT, which are normally involved in a delicate paracrine feedback loop in the growth plate. 13 Secondary osteosarcoma is extremely rare and only a few cases have been reported in the literature.
14 Unexpectedly, an intraosseous grade II osteosarcoma was found in the stalk of the osteochondroma of our patient. Intraosseous low grade (grade I-II) osteosarcomas comprise approximately 1% of all osteosarcomas. The duration of symptoms can be long and some patients are even asymptomatic. Patients treated with wide resection of a low grade osteosarcoma seem to have a good prognosis, with almost no chance of recurrence. Because the margins of the resected specimen from our patient were free of tumour the operation was considered adequate for both the chondrosarcoma and the osteosarcoma.
"The suspicion of secondary chondrosarcoma is indicated by growth of the tumour after puberty, the presence of pain, or a thickness over 1 cm of the cartilaginous cap in adults"
In the differential diagnosis one could consider dedifferentiated chondrosarcoma secondary to osteochondroma in this case. Dedifferentiated chondrosarcoma is defined as a high grade anaplastic sarcoma, next to a low grade malignant cartilaginous tumour. However, first, the osteosarcomatous part was situated in the stalk of the original osteochondroma separately from the cartilaginous cap comprising the chondrosarcoma. In dedifferentiated chondrosarcoma, the anaplastic component emerges from the low grade chondrosarcomatous part. Second, in our present case the osteosarcomatous part was a low to intermediate grade, whereas the anaplastic component of a dedifferentiated chondrosarcoma usually has a high grade appearance.
The development of three separate malignancies before the age of 40 in our patient is highly unusual, and suggests that he is genetically prone to malignant transformation. We expected an EXT germline mutation to be present in our patient. Both the EXT1 and EXT2 genes, which have been reported to show linkage in about 70% of the HME families, were screened for mutations. However, we found no aberrant bands by SSCP analysis, either because of the relatively low sensitivity of SSCP mutation analysis (70-90%), or because another (EXT) gene is responsible for the phenotype of our patient. A candidate would be the putative EXT3 gene on chromosome 19p. Interestingly, the occurrence of familial thyroid tumours was linked to 19p13.2, 15 raising the possibility of a contiguous gene deletion syndrome at 19p in our patient. However, it must be noted that even in the presence of a constitutional EXT mutation, the development of three malignancies is highly unusual. Although the family history did not indicate the presence of a Li-Fraumeni (-like) syndrome, we investigated the p53 gene, which is known to cause a variety of cancers at a young age when mutated in the germline. 16 p53 overexpression was restricted to the grade II osteosarcoma. We found no mutations in exons 5-8, the exons bearing 87% of the mutations found in p53.
In conclusion, we present the unusual case of a patient with HME who had a secondary chondrosarcoma in the cartilaginous cap and an intermediate grade osteosarcoma in the stalk of an osteochondroma. In addition, the patient had a history of a papillary thyroid carcinoma four years previously. Although no mutations were found in the genes involved in HME, or in the p53 gene, the development of three malignancies before the age of 40 suggests that this patient is genetically prone to malignant transformation.
Take home messages
• The development of three separate malignancies before the age of 40 in our patient suggests that he is genetically prone to malignant transformation • However, no mutations were found in the EXT1 and EXT2 genes, the genes involved in HME, or in the p53 gene • Osteosarcoma can rarely arise secondary to osteochondrosarcoma
